Stockscreener 앱 받기
8.43
0.48%
0.04
시간 외 거래:
8.43
전일 마감가:
$8.39
열려 있는:
$8.31
하루 거래량:
779.24K
Relative Volume:
0.52
시가총액:
$744.62M
수익:
$67.48M
순이익/손실:
$-278.67M
주가수익비율:
-2.6531
EPS:
-3.1774
순현금흐름:
$-70.70M
1주 성능:
-4.64%
1개월 성능:
-1.75%
6개월 성능:
+2.18%
1년 성능:
+15.96%
1일 변동 폭
$8.1725
$8.52
1주일 범위
$8.1725
$9.00
52주 변동 폭
$5.41
$12.49
Kura Oncology Inc Stock (KURA) Company Profile
명칭
Kura Oncology Inc
전화
(858) 500-8800
주소
4930 DIRECTORS PLACE, SUITE 500, SAN DIEGO, CA
Compare KURA vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KURA
Kura Oncology Inc
|
8.43 | 741.09M | 67.48M | -278.67M | -70.70M | -3.1774 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Kura Oncology Inc Stock (KURA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-04 | 개시 | Guggenheim | Neutral |
| 2025-02-06 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-10-14 | 다운그레이드 | Stifel | Buy → Hold |
| 2023-12-22 | 개시 | Mizuho | Buy |
| 2023-08-11 | 개시 | BofA Securities | Buy |
| 2023-07-27 | 개시 | Scotiabank | Sector Perform |
| 2023-05-17 | 개시 | BTIG Research | Buy |
| 2023-01-31 | 개시 | Stifel | Buy |
| 2022-07-12 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-02-15 | 개시 | Jefferies | Buy |
| 2021-05-05 | 재개 | Credit Suisse | Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2020-12-07 | 재확인 | H.C. Wainwright | Buy |
| 2020-12-03 | 개시 | Stifel | Buy |
| 2020-11-05 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2020-07-07 | 개시 | Credit Suisse | Outperform |
| 2020-05-05 | 개시 | Barclays | Overweight |
| 2019-07-18 | 개시 | Deutsche Bank | Buy |
| 2018-11-09 | 개시 | Piper Jaffray | Overweight |
| 2018-08-01 | 개시 | H.C. Wainwright | Buy |
| 2016-10-13 | 재개 | Leerink Partners | Outperform |
| 2016-01-22 | 개시 | JMP Securities | Mkt Outperform |
| 2015-12-30 | 개시 | Oppenheimer | Outperform |
| 2015-12-16 | 개시 | Citigroup | Buy |
모두보기
Kura Oncology Inc 주식(KURA)의 최신 뉴스
Kura Oncology Inc Stock (ISIN: US50126D1028) Faces Post-Earnings Pressure Amid Komzifti Launch Chall - AD HOC NEWS
Kura Oncology, Inc. (NASDAQ:KURA) Q4 2025 earnings call transcript - MSN
Kura Oncology anticipates $7B AML opportunity as KOMZIFTI launches and combination strategies advance - MSN
UBS Maintains Buy on KURA (Kura Oncology) March 2026, PT $15 - Meyka
Prosight Management LP Sells 422,668 Shares of Kura Oncology, Inc. $KURA - MarketBeat
UBS lowers Kura Oncology stock price target to $15 on launch data - Investing.com Canada
KURA SEC FilingsKura Oncology Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Implied volatility surging for Kura Oncology stock options - MSN
Implied Volatility Soars for Kura Oncology Option Contracts - Bitget
Kura Oncology at Barclays Conference: Strategic Focus on Drug Combinations - Investing.com Canada
Implied Volatility Surging for Kura Oncology Stock Options - Yahoo Finance
(KURA) Risk Channels and Responsive Allocation - Stock Traders Daily
Kura Oncology Inc earnings missed by $0.66, revenue fell short of estimates - Investing.com Nigeria
Kura Oncology at Leerink Global Healthcare Conference: Strategic Expansion Insights - Investing.com Canada
KURA: Rapid market access and robust pipeline drive growth and leadership ambitions in precision oncology - TradingView
KURA: Multiple clinical readouts and strong commercial momentum position for leadership in targeted oncology - TradingView
FY2027 EPS Forecast for Kura Oncology Lowered by Analyst - MarketBeat
How The Kura Oncology (KURA) Story Is Shifting With Komzifti And New Street Targets - Yahoo Finance
UBS Reaffirms Their Buy Rating on Kura Oncology (KURA) - The Globe and Mail
Kura Oncology rises after new early-stage trial data for leukemia therapy - MSN
Jim Cramer discusses Kura Oncology as a speculative bet - MSN
Kura Oncology 2025 Financials: Q4 Loss Widens, Misses Analyst EstimatesNews and Statistics - IndexBox
Kura Oncology Q4 2025 earnings preview - MSN
Kura Oncology, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:KURA) 2026-03-06 - Seeking Alpha
Kura Oncology, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Kura Oncology Reports $0.92 Q4 Loss Even as KOMZIFTI Debuts With $2.1M in Sales - AlphaStreet
Kura Oncology (NASDAQ:KURA) Given New $36.00 Price Target at Wedbush - MarketBeat
Kura Oncology, Inc. (NASDAQ:KURA) Q4 2025 Earnings Call Transcript - Insider Monkey
Kura Oncology reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Kura Oncology (KURA) Grants Stock Options to New Employees - GuruFocus
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Kura Oncology Q4 Earnings Call Highlights - MarketBeat
Kura Oncology Inc (KURA) Q4 2025 Earnings Call Highlights: KOMZIFTI Launch Boosts Revenue Amid ... By GuruFocus - Investing.com Canada
Wedbush Cuts Kura Oncology Price Target to $36 From $38, Outperform Rating Maintained - marketscreener.com
Kura Oncology Inc (KURA) Q4 2025 Earnings Call Highlights: KOMZI - GuruFocus
Kura Oncology (KURA) Reports Strong Q4 2025 with KOMZIFTI Launch - GuruFocus
Kura Oncology, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Kura Oncology (NASDAQ:KURA) Shares Gap Down After Earnings Miss - MarketBeat
Kura Oncology (NASDAQ:KURA) Releases Quarterly Earnings Results, Misses Estimates By $0.20 EPS - MarketBeat
Earnings call transcript: Kura Oncology Q4 2025 sees significant earnings miss, stock dips - Investing.com
Kura Oncology (KURA) Reports Q4 Loss, Misses Revenue Estimates - sharewise.com
KURA: KOMZIFTI launch and pipeline progress drive growth, targeting major cancer markets - TradingView
Kura Oncology, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Kura Oncology Reports Q4 Earnings Miss - National Today
Kura Oncology 10-K: $67.5M revenue; R&D $251.1M, SG&A $120.0M - TradingView
Kura Oncology: Q4 Earnings Snapshot - KVUE
Kura Oncology: Fourth Quarter Financial Results Overview - Bitget
Kura Oncology (KURA) Faces Mixed Financial Results Amid Promisin - GuruFocus
Earnings Flash (KURA) Kura Oncology Posts Q4 Loss $0.92 a Share, vs. FactSet Est of $0.64 Loss - marketscreener.com
KURA ONCOLOGY ($KURA) Releases Q4 2025 Earnings - Quiver Quantitative
Kura Oncology Inc. Q4 Loss Increases - Nasdaq
Kura Oncology Inc (KURA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):